Regeneron Pharmaceuticals Management

Management criteria checks 3/4

Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.25 years. total yearly compensation is $8.18M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth $2.16B. The average tenure of the management team and the board of directors is 6.6 years and 17.3 years respectively.

Key information

Leonard Schleifer

Chief executive officer

US$8.2m

Total compensation

CEO salary percentage	22.9%
CEO tenure	36.3yrs
CEO ownership	2.2%
Management average tenure	6.6yrs
Board average tenure	17.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Leonard Schleifer's remuneration changed compared to Regeneron Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

Compensation vs Market: Leonard's total compensation ($USD8.18M) is above average for companies of similar size in the UK market ($USD5.65M).

Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.

CEO

Leonard Schleifer (70 yo)

36.3yrs

Tenure

US$8,184,338

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Leonard Schleifer	Co-Founder	36.3yrs	US$8.18m	2.24% $ 2.2b
George Yancopoulos	Co-Founder	23.3yrs	US$7.76m	1.21% $ 1.2b
Andrew Murphy	Executive Vice President of Research	5.3yrs	US$8.43m	0.049% $ 47.0m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16yrs	US$8.76m	0.031% $ 30.2m
Christopher Fenimore	Senior VP of Finance & CFO	less than a year	no data	0.023% $ 21.8m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.3yrs	no data	no data
Bob McCowan	Senior VP of IT & Chief Information Officer	3.3yrs	no data	no data
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	no data	no data
Joseph LaRosa	Executive VP	12.6yrs	US$7.13m	0.037% $ 35.9m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.3yrs	no data	no data
Christina Chan	Senior Vice President of Corporate Affairs	no data	no data	no data
Sally Paull	Executive Vice President of Human Resources	8yrs	no data	no data

6.6yrs

Average Tenure

63.5yo

Average Age

Experienced Management: 0R2M's management team is seasoned and experienced (6.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Schleifer	Co-Founder	36.3yrs	US$8.18m	2.24% $ 2.2b
George Yancopoulos	Co-Founder	23.3yrs	US$7.76m	1.21% $ 1.2b
Christine Poon	Lead Independent Director	13.4yrs	US$748.01k	0.00073% $ 702.9k
Arthur Ryan	Independent Director	21.3yrs	US$724.99k	0.017% $ 16.2m
Michael Brown	Independent Director	32.8yrs	US$728.99k	0.012% $ 11.2m
Joseph Goldstein	Independent Director	32.8yrs	US$709.99k	0.0046% $ 4.5m
George Sing	Independent Director	36.3yrs	US$724.99k	0.026% $ 25.4m
N. Coles	Independent Director	7.3yrs	US$704.99k	0.000010% $ 9.6k
Craig Thompson	Independent Director	1.5yrs	US$247.79k	0.00042% $ 404.4k
Huda Zoghbi	Independent Director	7.6yrs	US$714.99k	0% $ 0
Bonnie Bassler	Independent Director	7.6yrs	US$709.99k	0.0013% $ 1.2m
Kathryn Guarini	Independent Director	less than a year	US$1.03m	no data

17.3yrs

Average Tenure

70yo

Average Age

Experienced Board: 0R2M's board of directors are seasoned and experienced ( 17.3 years average tenure).

Regeneron Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Insider recently sold US$7.6m worth of stock

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Recent updates

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. Announces Two-Year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-Related Macular Degeneration

Second quarter 2023 earnings released: EPS: US$9.05 (vs US$7.90 in 2Q 2022)

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal PHOTON Trial Investigating Aflibercept 8 mg with 12- and 16-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

FDA Issues Complete Response Letter (CRL) for Aflibercept 8 Mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings At A Third-Party Filler

Regeneron Pharmaceuticals, Inc. Provides Updated Data from Two Phase 2 Expansion Dose Cohorts Evaluating Investigational Linvoseltamab

Full year 2022 earnings released: EPS: US$40.51 (vs US$76.40 in FY 2021)

Now 25% undervalued after recent price drop

Now 20% undervalued

Now 20% undervalued

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approved Eylea Injection

Full year 2022 earnings released: EPS: US$40.51 (vs US$76.40 in FY 2021)

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Expands the Marketing Authorization for Dupixent® (Dupilumab) in the European Union

Now 24% undervalued after recent price drop

Regeneron Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Receives Approval in Japan for Advanced or Recurrent Cervical Cancer

Regeneron Pharmaceuticals, Inc. Demonstrates High and Durable Complete Response Rate Among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial

Regeneron Pharmaceuticals, Inc. Announces Pivotal Odronextamab (Cd20xcd3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Debut At ASH

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types

Evkeeza(R) (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

Regeneron Pharmaceuticals, Inc Announces Dupixent® (Dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

Regeneron Pharmaceuticals, Inc. Announces Libtayo in Combination with Chemotherapy Approved by the FDA as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Regeneron Pharmaceuticals, Inc. Updates Results from Two Positive Pivotal Trials Investigating Novel Aflibercept 8 Mg with 12- and 16-Week Dosing Regimens

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age